Healthcare / BiotechnologyTaipei Exchange
$33.40
+0.55 (+1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-47.2M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.4%
↓Gross Margin
32.4%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+48.0%
FCF CAGR
—
FCF margin
-837.0%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.5M · net income $-53.8M · FCF $-46.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.5M | $5.5M | $203000.00 | $805000.00 | $1.7M |
| Net Income | $-53.8M | $-53.8M | $-78.3M | $-68.2M | $-41.2M |
| EBITDA | $-46.5M | $-46.5M | $-71.6M | $-61.5M | $-34.3M |
| EPS | — | — | -1.75 | -1.81 | -1.28 |
| Gross Margin | 32.4% | 32.4% | 4.9% | 38.9% | 56.4% |
| Operating Margin | -1363.3% | -1363.3% | -44142.9% | -9156.5% | -2729.8% |
| Net Margin | -969.3% | -969.3% | -38561.1% | -8467.0% | -2403.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.06 | 0.06 | 0.11 |
| Cash Flow | |||||
| Free Cash Flow | $-46.4M | $-46.4M | $-83.4M | $-47.2M | $-35.8M |
| Returns | |||||
| ROE | -10.4% | -10.4% | -19.9% | -14.5% | -14.7% |
| Valuation | |||||
| P/B | 3.58 | 3.58 | 1.93 | 1.94 | — |
| Growth & Yield | |||||
| Revenue Growth | 2633.0% | 2633.0% | -74.8% | -53.0% | — |
| EPS Growth | — | — | 3.5% | -41.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+97.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.75 → n/d
Residual
+97.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.